{
  "docId": "019de070-c935-736b-bfac-0e59550f8f0f",
  "docSlug": "bbdd6d1004c11d68b286eff6aee60dc0",
  "documentTitle": "argenx SE | Results Presentation Deck | 20 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 20,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "propose_solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The chart shows a positive correlation between IgG reduction and clinical improvement in MG-ADL scores.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-c935-736b-bfac-0e59550f8f0f/7",
  "deckHref": "/decks/019de070-c935-736b-bfac-0e59550f8f0f",
  "deckJsonHref": "/decks/019de070-c935-736b-bfac-0e59550f8f0f.json",
  "deckAnchorHref": "/decks/019de070-c935-736b-bfac-0e59550f8f0f#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.05,
        "y": 0.38
      },
      "kind": "chart",
      "text": "Correlation between IgG reduction and MG-ADL change",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "19663c65-cf90-4498-870d-56fd904a8770",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.83,
        "y": 0.02
      },
      "kind": "image",
      "text": "adapt SC logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41d942ef-ff09-4157-8108-2afe20a68742",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.55,
        "y": 0.38
      },
      "kind": "list",
      "text": "Study designed to demonstrate non-inferiority of PD effect of 1000 mg SC efgartigimod to 10mg/kg IV efgartigimod; Phase 1 HV data showed similar PD effect; Additional patients from ADAPT+ to transition; Primary endpoint assessment at day 29",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a9e36b98-48df-4fa0-96c9-777a79b3cd43",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.65,
        "x": 0.04,
        "y": 0.07
      },
      "kind": "title",
      "text": "SC Bridging Strategy Leverages Correlation Between Pharmacodynamic and Clinical Effect",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ea64498-a460-4235-83b6-ee470e502ecc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 4,
      "beatId": "370e7a7b-342c-4314-a537-20aca17005f0",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Rising Success",
      "beatSlug": "rags-to-riches-rising-success",
      "evidence": "The presentation highlights the company's promising pipeline and clinical trials",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}